


FIG. 1



⊠ 0001

SK-OV-3

EY

OVCAR-3

U JURKAT

M LANCAP

FTC

☐ FS

12 HUVEC

FIG. 2




FIG. 3





FIG. 4






FIG. 6




FIG. 7



FIG. 8








FIG. 9B











-DMBA

DABA .





B - DMBA




FIG. 12




FIG. 13




FIG. 14





FIG. 15



FÍG. 16




FIG. 17A

Retention Time

FIG. 17B




FIG. 18A






FIG. 18B




FIG. 18C




FIG. 18D




FIG. 18E





FIG. 18F



sub G-0 (0.9%)
G-1 (47.9%)
S (36.1%)

Ø G-2+M (6.8%)

FIG. 19A




FIG. 19B

区 sub G-0 (1.6%) 区 G-1 (57.4%) 区 S (26.8%) t 区 G-2 + M (8.8%)





1 2 3 4 5 6 7 8 9 10 NF-кВ →

1:Untreated

2:TNF (100pM)

3: F035 (1ug/ml)

4: TNF+ F035 (1ug/ml)

5: F035 (2µg/ml)

6: TNF+ F035 (2μg/ml)

 $7 : F094 (1 \mu g/ml)$

 $8 : TNF+F094 (1\mu g/ml)$

9: F094 (2ug/ml)

10: TNF+ F094 (2ug/ml)




FIG 21




FIG 22





FIG 23

T. A.


STRUCTURE OF LIPTOSIDES: ELLIPTOSIDE E if R=OH ELLIPTOSIDE A if R=H

FIG 24




HPLC separation of the constituents in F094

FIG 25




HPLC separation of the constituents in F035

FIG 26




First Fractionation by Semi-Prep HPLC of F094

FIG 27



Second Fractionation by Semi-Prep HPLC of F094

FIG 28



Prep Fractionation of F094

FIG 29




FIG 30






FIG 31




G1 after second PFP column purification.

FIG 32




G1 after final C-18 purification

FIG 33




D1 after Waters C-18 column purification.

FIG 34




D1 after final C18-Aq purification

FIG 35




Compounds from the Degradation of D1



· Compounds from the Degradation of G1

用图37




Compounds from the Degradation of B1

FIG. 39


FIG. 40

FIG. 41



DAGGESS LIISCI






Ы

В

In the first man man man








FIG 45.5



Fold Activation 1.0 3.9 1.1 1.7 1.2 1.5 0.9 1.1 1.0 1.1

В






FIG 46




FIG 47

Effect of z-vad fmk on F035 induced PARP cleavage in Jurkat cells

F035 - + - + z-vad fmk - - + +

Effect of F035, F094, D1 & G1 on caspase activity in Jurkat cells.




FIG 49

time (h) 0. 4 6

Cytochrome c

FIG 50

The state of the s







FIG. 51 A-B


Cold mut TNF









G B p65





B




 \mathbf{C}



→ NF-ĸB

B

A



Untreated

LPS

LPS


F094

F094 + LPS

Avicin G + LPS

Avicin G + LPS

FIG. 55 A, B



HPLC Separation of the Avicins in F094

0.331-0.407 μg/ml


IC₅₀ Values

Avicin D

$$0.320-0.326 \,\mu g/ml$$

Avicia G

0.160-0.181 µg/ml



EIG. 57

Time (h) 0 0.5 1 2 4

Mixture

Fold increase

1.0 0.8 0.8 1.3 1.5



Avicin D

Fold increase

1.0 1.5 1.7 1.9 3.5



Avicin G

Fold increase

1.0 3.5 4.7 6.3 8.4

A

Time (min) 0 1 2 5 10 20

B Avicin G (µg/ml) + S S S S N N

C

DEVD


2VAD-fmk

Avicin G

DEVD+Avicin G

ZVAD-fmk+Avicin G

 \mathbf{B}






FIG. 60





FIG. 61



This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ OTHER:

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.